This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

It could be due to or be exacerbated by PD treatment and, vice versa, it could determine an alteration in the pharmacokinetic of dopaminergic medications. Patients should be counseled on the ...

Although dopaminergic medication may also improve sleep quality by reducing sleep onset latency (the time taken to fall asleep) and wakefulness in PD patients, there are documented reports of ...

with or without dopaminergic medications. Amantadine has been approved since the 1970s to treat Parkinson’s but Adamas has produced it in an extended release formulation to allow for a gradual ...

There is now robust experimental evidence for a neuroprotective effect of nicotine upon dopaminergic neurons ... that nicotine or nicotinic receptor drugs have therapeutic potential for ...

8 Box 1 provides a summary of the PD medications that could confound the results of biochemical tests for pheochromocytoma. Patients with PD might have to be taken off their dopaminergic ...